Overview

Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Safety, tolerability and pharmacokinetics
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Epinastine